Precision Onco Ltd 3
3 · CONSTELLATION PHARMACEUTICALS INC · Filed Jul 18, 2018
Insider Transaction Report
Form 3
Precision Onco Ltd
10% Owner
Holdings
Series F Preferred Stock
→ Common Stock (317,921 underlying)
Footnotes (1)
- [F1]The Series F Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.